Clinical impact of multidrug-resistant organisms in liver cirrhosis: A retrospective cohort study in the intensive care setting

Table 6 Clinical outcomes stratified by decompensation phenotype (acute decompensation vs acute-on-chronic liver failure), n (%)/median (interquartile range)

Outcome	AD (n = 20)	ACLF (n = 87)	P value1
MDRO colonized	2 (10.0)	30 (34.5)	0.033a
Total infections	16 (80.0)	75 (86.2)	0.494
Strain-concordant infection	2 (100.0)	18 (81.8)	1.000
ICU length of stay (days)	5.0 (7.5)	9.0 (12.0)	0.084
28-day transplant-free survival	15 (75.0)	34 (39.1)	0.008b
ICU survival	17 (85.0)	38 (43.7)	0.001c
Hospital survival	15 (75.0)	30 (34.5)	0.002d
Hospital LOS (days)	20.5 (25.2)	24.0 (24.0)	0.946

^aP < 0.05 for multidrug-resistant organism colonization (acute-on-chronic liver failure vs acute decompensation).

^bP < 0.01 for 28-day transplant-free survival (acute-on-chronic liver failure vs acute decompensation).

^cP < 0.01 for intensive care unit survival (acute-on-chronic liver failure vs acute decompensation).

^dP < 0.01 for hospital survival (acute-on-chronic liver failure vs acute decompensation).

¹P values were calculated using Fisher’s exact or Mann-Whitney U test, as appropriate.

MDRO: Multidrug-resistant organism; ICU: Intensive care unit; LOS: Length of stay; AD: Acute decompensation; ACLF: Acute-on-chronic liver failure.